drugset
drugset / Trial / NCT05722977

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

NCT05722977 ↗

Phase 2 Not yet recruiting 45 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelTreatment

Summary

In this study, we investigated the efficacy and safty of surufatinib combined with envafolimab followed by surufatinib as second or more - line therapy in advanced soft tissue sarcoma patients. Patients who have failed at least the first-line therapy and have progressive disease or cannot tolerate within 6 months before enrollment will be treated with surufatinib combined with envafolimab.

Timeline

Start
2023-02-02
Primary completion
2026-02-02
Completion
2027-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Envafolimab Monoclonal antibody 300 mg Subcutaneous
Subject Surufatinib Small molecule 250 mg Oral

Indications

No indication recorded.